- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06144268
Live Birth Rate After Sperm Selection Using ZyMōt Multi (850µL) Device for Intra Uterine Insemination (FERTINSEM)
Evaluation of Live Birth Rate After Sperm Selection Using Microfluidic Technology (ZyMōt Multi (850µL) Sperm Separation Device) for Intra Uterine Insemination.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Intrauterine insemination is a commonly used method for Medically Assisted Reproduction for patients with mild male factor infertility, anovulation, endometriosis, and unexplained infertility. It is also the procedure of choice in cases of lesbian couples or single women, using donor sperm.
During the IUI procedure, the sperm suspension is introduced into the uterus through the cervix canal using an insemination catheter containing 0.4 ml sperm. Before sperm can be used in IUI, it must first be processed. The aim of semen preparation is to select the best sperm cell population (highly motile, morphologically normal spermatozoa with minimal DNA damage) with the highest fertilization potential.
One of the most used sperm preparation technique is DGC. This technique allows the separation of sperm cells based on their density. Morphologically normal and abnormal spermatozoa have different densities. A mature morphologically normal spermatozoon has a slightly higher density, whereas an immature and morphologically abnormal spermatozoon has a lower density. During this procedure, raw semen sample is placed on 2 gradients: a lower phase (80%) and an upper phase (40%) followed by centrifugation. The composition of the gradients include a colloidal suspension of silica particles. At the end of centrifugation, each spermatozoa is situated at the gradient level that matches its density. The highly motile, morphologically normal, viable spermatozoa form a pellet at the bottom of the tube. This procedure is relatively easy to perform but both the centrifugation steps and the silica particle are considered to have a negative impact on DNA integrity.
Recently, microfluidic technology was introduced as an alternative to the conventional sperm sorting techniques. As this procedure does not require semen processing, it reduces the sperm preparation time and eliminates sperm DNA damaging procedures (e.g. by centrifugation). This technology is a chemical-free method of sorting healthy normal sperm using a sterile disposable ZyMōt Multi (850µL) sperm separation device. Sperm selected by this device proved to have better motility and less DNA damage compared to DGC procedure. More recently, the efficacy of this device has been reported to significantly increase ongoing pregnancy rate when compared with DGC in IUI cycles. However, large, correct studies that investigate live birth rate are missing.
The present study aims to determine whether the use of ZyMōt Multi (850µL) device for sperm selection improves the live birth rate in IUI patients as compared to the standard DGC procedure. Couples undergoing IUI procedure will be included in the study if they are planned for IUI with fresh autologous ejaculate.
Patients that fulfill the inclusion criteria will be randomly allocated to one of the two sperm selection methods: DGC (standard) or ZyMōt Multi (850µL) device (treatment) groups. The randomization will be performed based on an electronically generated list. A patient participation to the study will be limited to 3 consecutive IUI attempts (within a period of 6 months). Same semen preparation protocol used in the 1st IUI attempt [ZyMōt Multi (850µL) or DGC] will be used in the next 2 consecutive IUIs. Following the IUI procedure (with sperm selected with either one of the two methods), the patients will be monitored for pregnancy, clinical pregnancy and neonatal outcome.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Elsie Nulens
- Phone Number: 0032 2 4742676
- Email: elsie.nulens@uzbrussel.be
Study Contact Backup
- Name: Ileana Mateizel, PhD
- Phone Number: 0032 24749119
- Email: ileana.mateizel@uzbrussel.be
Study Locations
-
-
-
Brussels, Belgium, 1090
- Recruiting
- UZ Brussel CRG
-
Contact:
- Ileana G Mateizel, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Fresh autologous ejaculate
- Female age: <37 at start of the first insemination
- 1st IUI ever here, maximum 3 consecutive IUIs during max 6 months
- BMI <35
- All natural cycles, ovulation induction allowed
- Presence of 1 or 2 follicles at the last ultrasound
- Regular menses (26-35 days)
- >1 million Total Progressive Motile Sperm Count (TPMC) after previous routine capacitation with DGC
- Presence of at least 1 potent tube after Hyfosy
Exclusion Criteria:
- Presence of intracavitary pathology at ultrasound
- Evidence of advance endometriosis (Grade 3 and 4)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Density Gradient Centrifugation (DGC)
During this procedure, raw semen sample is placed on 2 gradients: a lower phase (80%) and an upper phase (40%) followed by centrifugation.
The composition of the gradients include a colloidal suspension of silica particles.
At the end of centrifugation, each spermatozoa is situated at the gradient level that matches its density.
The highly motile, morphologically normal, viable spermatozoa form a pellet at the bottom of the tube.
|
The gradient columns will be prepared by placing 1 ml 80% gradient media in a centrifuge tube and an additional 1 ml of 40% gradient layered on top. The raw semen sample will be placed on top of the gradient (1ml semen/gradient tube) and centrifuged at 300xg for 20 minutes. The sperm pellet will be collected and washed 2 times for 5 min at 800xg in Sage Quinn's AdvantageTM Medium with Hepes + 5% HSA-solution. The resulted pellet will be resuspended in the washing solution in a volume that will provide at least 1x106 forward motile spermatozoa in 400 µl, as this amount is necessary for IUI procedure. |
Experimental: ZyMōt Multi (850µL)
ZyMōt Multi (850µL) is a flow-free dual chambered single-use device.
The first chamber contains a sample inlet and a fluid channel separated from the second collection chamber by an 8-μm microporous membrane.
Channel dimension and membrane porosity are designed to optimize the sorting and collection of the most motile sperm.
Sorting is accomplished by the passage of sperm through the micropores of the membrane.
This procedure does not require any preliminary semen processing, all centrifugation steps being eliminated.
|
An amount of 850 µl untreated semen sample will be loaded into the inlet chamber with a help of a sterile insulin-type syringe.
A volume of 750 µl of Sage Quinn's AdvantageTM Medium with Hepes + 5% HSA-solution medium will be placed on top of the membrane (outlet chamber).
After 30 min of incubation in a humidified incubator (37°C), 500 µl of medium, containing the selected spermatozoa, will be retrieved from the upper side of the membrane (retrieval chamber).
An amount of 400 µl will be necessary for the IUI procedure.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cumulative live birth rate after 3 consecutive IUIs
Time Frame: 9 months following IUI
|
Number of live births per number of inseminations
|
9 months following IUI
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pregnancy rate
Time Frame: 14 days following IUI
|
number of pregnancies (positive hCG) per number of inseminations
|
14 days following IUI
|
Miscarriages rate
Time Frame: 12 weeks following IUI
|
number of miscarriages per number of inseminations
|
12 weeks following IUI
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Shari Mackens, MD, PhD, Universitair Ziekenhuis Brussel
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EC-2023-257
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infertility
-
Assuta Hospital SystemsMaccabi Healthcare Services, IsraelCompletedInfertility, Female Infertility, Male InfertilityIsrael
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedPregnancy | Male Infertility | Female InfertilityNetherlands
-
Sapientiae InstituteTerminated
-
Esraa Gamal AhmedAin Shams Maternity HospitalUnknownUnexplained Female Infertility
-
King's College LondonNot yet recruitingInfertility | Infertility, Female | Infertility Unexplained | Infertility of Tubal Origin
-
Gazi UniversityCompletedMale Infertility | Unexplained Infertility
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedMale Infertility, AzoospermiaUnited States
-
Pacific Fertility CenterTerminatedPrimary Female Infertility | Secondary Female Infertility
-
Wake Forest University Health SciencesWithdrawnUterine Diseases | Endometriosis | Infertility Unexplained | Endometrial Diseases | Infertility; Female, NonimplantationUnited States
-
Istanbul University - Cerrahpasa (IUC)RecruitingInfertility | Sexual Dysfunction | Infertility, Male | Nurse's Role | Sexuality | Infertility; FemaleTurkey
Clinical Trials on Density Gradient Centrifugation
-
Bezmialem Vakif UniversityUnknownInfertility, Male | Infertility UnexplainedTurkey
-
Bezmialem Vakif UniversityYeditepe University HospitalCompletedMale Infertility | Infertility, MaleTurkey
-
Professor Ernest Hung-Yu NgRecruiting
-
University of California, San FranciscoRecruitingInfertility | Fertility Disorders | Anovulation | Reproductive Issues | Infertility Unexplained | Infertility SecondaryUnited States
-
NYU Langone HealthCompleted
-
Lawrence EngmannThe Center for Advanced Reproductive Services, P.C.; ZyMot FertilityActive, not recruitingInfertility | Recurrent Pregnancy LossUnited States
-
Professor Ernest Hung-Yu NgNot yet recruitingInfertility | Aneuploidy | Genetic Disease | Chromosomal RearrangementChina
-
Professor Ernest Hung-Yu NgNot yet recruiting
-
Ganin Fertility CenterThe Cleveland Clinic; University of the Western CapeCompletedGender Ratio of ICSI OutcomeEgypt
-
Ganin Fertility CenterCompleted